Black Rock Inc. Rain Therapeutics Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.84 - $1.22 $63,270 - $91,892	75,322 Added 7.42%	1,090,707 $1.31 Million
Q3 2023 Nov 13, 2023	SELL	$0.82 - $1.42 $938 - $1,625	-1,145 Reduced 0.11%	1,015,385 $873,000
Q2 2023 Aug 11, 2023	BUY	$1.09 - $9.93 $1.03 Million - $9.34 Million	941,037 Added 1246.52%	1,016,530 $1.22 Million
Q1 2023 May 12, 2023	BUY	$7.77 - $12.47 $202,789 - $325,454	26,099 Added 52.84%	75,493 $659,000
Q4 2022 Feb 13, 2023	SELL	$5.52 - $8.48 $488,790 - $750,895	-88,549 Reduced 64.19%	49,394 $395,000

Q3 2022 Nov 14, 2022	SELL	$4.75 - $8.01 $19,247 - $32,456	-4,052 Reduced 2.85%	137,943 $673,000
Q2 2022 Aug 12, 2022	SELL	$2.21 - $5.56 $1.46 Million - $3.68 Million	-661,216 Reduced 82.32%	141,995 $790,000
Q1 2022 May 12, 2022	BUY	$5.07 - $13.68 $316,063 - $852,811	62,340 Added 8.41%	803,211 $4.07 Million
Q4 2021 Feb 10, 2022	BUY	$11.91 - $17.0 $4.38 Million - $6.26 Million	368,124 Added 98.76%	740,871 $9.54 Million
Q3 2021 Nov 09, 2021	BUY	$13.21 - $20.91 $200,250 - $316,974	15,159 Added 4.24%	372,747 $5.58 Million
Q2 2021 Aug 11, 2021	BUY	$15.08 - $20.3 $5.39 Million - $7.26 Million	357,588 New	357,588 $5.56 Million

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.